PRMT3 and metabolic dysfunction-associated steatotic liver disease: In further support of the notion that PRMT3 inhibition can potentially serve as a novel therapeutic approach to reduce non-alcoholic fatty liver disease burden, we have shown that chronic treatment with SGC707 is also associated with markedly reduced triglyceride levels in livers of hypercholesterolemic apolipoprotein E (apoE) knockout mice after an atherogenic Western-type, high cholesterol / high fat diet challenge6.